Monopar Therapeutics Inc. Accumulated Other Comprehensive Income
Monopar Therapeutics Inc. (MNPR) had Accumulated Other Comprehensive Income of $91.32 thousand as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-08-12
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $91.32K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $98.52K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $131.39K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $11.70K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | $91.32K 10-Q · filed 2026-08-12 |
| 2026-03-31 | $98.52K 10-Q · filed 2026-05-14 |
| 2025-12-31 | $131.39K 10-Q · filed 2026-08-12 |
| 2025-09-30 | $11.70K 10-Q · filed 2025-11-13 |
| 2025-06-30 | $77.58K 10-Q · filed 2025-08-12 |
| 2025-03-31 | -$21.78K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $35.99K 10-K · filed 2026-03-27 |
| 2024-09-30 | -$10.99K 10-Q · filed 2024-11-08 |
| 2024-06-30 | $8.26K 10-Q · filed 2024-08-09 |
| 2024-03-31 | $4.23K 10-Q · filed 2024-05-09 |
| 2023-12-31 | -$14.13K 10-K · filed 2025-03-31 |
| 2023-09-30 | $3.95K 10-Q · filed 2023-11-09 |
| 2023-06-30 | $7.22K 10-Q · filed 2023-08-10 |
| 2023-03-31 | $31.79K 10-Q · filed 2023-05-11 |
| 2022-12-31 | $8.94K 10-K · filed 2024-03-28 |
| 2022-09-30 | $42.98K 10-Q · filed 2022-11-10 |
| 2022-06-30 | $17.47K 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$3.74K 10-Q · filed 2022-05-12 |
| 2021-12-31 | -$3.16K 10-K · filed 2023-03-23 |
| 2021-09-30 | -$5.15K 10-Q · filed 2021-11-12 |
| 2021-06-30 | -$5.16K 10-Q · filed 2021-08-12 |
| 2021-03-31 | -$5.10K 10-Q · filed 2021-05-13 |
| 2020-12-31 | -$7.87K 10-K · filed 2022-03-24 |
| 2020-09-30 | -$10.04K 10-Q · filed 2020-11-12 |
| 2020-06-30 | -$11.55K 10-Q · filed 2020-08-06 |
| 2020-03-31 | -$15.01K 10-Q · filed 2020-05-07 |
| 2019-12-31 | -$10.97K 10-K · filed 2021-03-25 |
| 2019-09-30 | -$12.20K 10-Q · filed 2019-11-12 |
| 2019-06-30 | -$23.94M 10-Q · filed 2019-08-08 |
| 2019-03-31 | -$4.52K 10-Q · filed 2019-05-10 |
| 2018-12-31 | -$2.40K 10-K · filed 2020-03-27 |
| 2018-09-30 | -$2.38K 10-Q · filed 2018-11-09 |
| 2018-06-30 | -$1.58K 10-Q · filed 2018-08-09 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |